Long-term prognostic and predictive factors in 107 stage 11/111 breast cancer patients treated with anthracycline-based neoadjuvant chemotherapy
1997

Long-term Factors in Breast Cancer Patients Treated with Neoadjuvant Chemotherapy

Sample size: 107 publication Evidence: moderate

Author Information

Author(s): E Brain, C Garrino, J-L Misset, I Garcia Carbonero, M ltzhaki, E Cvitkovic, E Goldschmidt, F Burki, C Regensberg, E Pappo, R Hagipantelli, M Musset

Primary Institution: Hôpital Paul Brousse

Hypothesis

The study aims to identify predictive and prognostic factors in breast cancer patients treated with neoadjuvant chemotherapy.

Conclusion

The study found that pathological evaluation of antitumoral activity is crucial for prognostic information in breast cancer patients treated with neoadjuvant chemotherapy.

Supporting Evidence

  • Median disease-free survival was 90.5 months.
  • Clinical response rates were 87% based on clinical evaluation.
  • Pathological complete response was associated with better outcomes.

Takeaway

Doctors wanted to see what helps predict how well treatment works for women with breast cancer who got chemotherapy before surgery. They found that looking at the tumor after treatment gives important clues.

Methodology

The study analyzed 107 women with stage II/III non-inflammatory breast carcinoma treated with anthracycline-based neoadjuvant chemotherapy followed by surgery, using univariate and multivariate analyses.

Potential Biases

Potential biases due to the retrospective nature and single-center design of the study.

Limitations

The study is retrospective and may not account for all variables affecting outcomes.

Participant Demographics

The study included 107 women with a median age of 52 years, with both premenopausal and post-menopausal participants.

Statistical Information

P-Value

p<0.05

Statistical Significance

p<0.05

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication